BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29334932)

  • 21. Factors associated with timely initiation of antiretroviral therapy in two HIV clinics in Lilongwe, Malawi.
    Johnson DC; Feldacker C; Tweya H; Phiri S; Hosseinipour MC
    Int J STD AIDS; 2013 Jan; 24(1):42-9. PubMed ID: 23467293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
    Sadeghi L; Moallemi S; Tabatabai RA; Esmaeilzadeh A; Ahsani-Nasab S; Ahmadi NE; Bayanolhagh S; Lolaie M; Narouei A; SeyedAlinaghi S; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):207-213. PubMed ID: 29308748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-associated anaemia before and after initiation of antiretroviral therapy at Art Centre of Minilik II Hospital, Addis Ababa, Ethiopia.
    Adane A; Desta K; Bezabih A; Gashaye A; Kassa D
    Ethiop Med J; 2012 Jan; 50(1):13-21. PubMed ID: 22519158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal Function Impairment and Associated Factors among HAART Naïve and Experienced Adult HIV Positive Individuals in Southwest Ethiopia: A Comparative Cross Sectional Study.
    Mekuria Y; Yilma D; Mekonnen Z; Kassa T; Gedefaw L
    PLoS One; 2016; 11(8):e0161180. PubMed ID: 27537338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
    Humphreys EH; Chang LW; Harris J
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA Paediatric West African Database to evaluate AIDS.
    Renner LA; Dicko F; Kouéta F; Malateste K; Gueye RD; Aka E; Eboua TK; Azondékon A; Okomo U; Touré P; Ekouévi D; Leroy V;
    J Int AIDS Soc; 2013 Sep; 16(1):18024. PubMed ID: 24047928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and outcomes of older HIV-infected patients receiving antiretroviral therapy in Malawi: A retrospective observation cohort study.
    Tweya H; Feldacker C; Heller T; Gugsa S; Ng'ambi W; Nthala O; Kalulu M; Chiwoko J; Banda R; Makwinja A; Phiri S
    PLoS One; 2017; 12(7):e0180232. PubMed ID: 28686636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
    Ssali F; Stöhr W; Munderi P; Reid A; Walker AS; Gibb DM; Mugyenyi P; Kityo C; Grosskurth H; Hakim J; Byakwaga H; Katabira E; Darbyshire JH; Gilks CF;
    Antivir Ther; 2006; 11(6):741-9. PubMed ID: 17310818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dyslipidemia among rural and urban HIV patients in south-east Malawi.
    Amberbir A; Singano V; Matengeni A; Ismail Z; Kawalazira G; Chan AK; Sodhi SD; van Oosterhout JJ
    PLoS One; 2018; 13(5):e0197728. PubMed ID: 29782548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile of HIV-infected patients receiving second-line antiretroviral therapy in a resource-limited setting in Nigeria.
    Onyedum CC; Iroezindu MO; Chukwuka CJ; Anyaene CE; Obi FI; Young EE
    Trans R Soc Trop Med Hyg; 2013 Oct; 107(10):608-14. PubMed ID: 23959002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss to follow-up before and after initiation of antiretroviral therapy in HIV facilities in Lilongwe, Malawi.
    Tweya H; Oboho IK; Gugsa ST; Phiri S; Rambiki E; Banda R; Mwafilaso J; Munthali C; Gupta S; Bateganya M; Maida A
    PLoS One; 2018; 13(1):e0188488. PubMed ID: 29373574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The burden of hypertension, diabetes mellitus, and cardiovascular risk factors among adult Malawians in HIV care: consequences for integrated services.
    Divala OH; Amberbir A; Ismail Z; Beyene T; Garone D; Pfaff C; Singano V; Akello H; Joshua M; Nyirenda MJ; Matengeni A; Berman J; Mallewa J; Chinomba GS; Kayange N; Allain TJ; Chan AK; Sodhi SK; van Oosterhout JJ
    BMC Public Health; 2016 Dec; 16(1):1243. PubMed ID: 27955664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.